Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Fair Value (Tables)

Fair Value (Tables)

3 Months Ended

Mar. 31, 2019

Schedule of financial assets measured at fair value on a recurring basis

Financial assets measured at fair value on a recurring basis are categorized in the tables below based upon the lowest level of significant input to the valuations (in thousands):


	Assets at Fair Value as of March 31, 2019
	Level 1		Level 2		Level 3		Total
Money market funds	$	10,334	$	—	$	—	$	10,334
U.S. treasury bills		—		2,293		—		2,293
Government-sponsored enterprise securities		—		2,486		—		2,486
Corporate bonds and commercial paper		—		111,514		—		111,514
Total	$	10,334	$	116,293	$	—	$	126,627


	Assets at Fair Value as of December 31, 2018
	Level 1		Level 2		Level 3		Total
Money market funds	$	9,106	$	—	$	—	$	9,106
Government-sponsored enterprise securities		—		7,872		—		7,872
Corporate bonds and commercial paper		—		108,933		—		108,933
Total	$	9,106	$	116,805	$	—	$	125,911